Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Statement Of Investor Complaints For The Quarter Ended December 31, 2017

 In compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith a statement for the quarter ended December 31, 2017,giving number of investor complaints pending at the beginning of the quarter, those received during the quarter, disposed of during the quarter and those remaining unresolved if any, at the end of the quarter. Request you to take the same on record.
15-01-2018
Bigul

This $17 billion dilemma will make or break Reckitt's CEO Rakesh Kapoor: Gadfly

 Pfizer isn't the only route to solving Reckett's growth problem. Some are less obvious, but that's not an issue for Kapoor as he has a habit of doing the unexpected.
27-12-2017
Bigul

Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Listing Regulations, please find below details of the meeting scheduled with an Analyst/Institutional Investor: Day and Date : Friday, December 8, 2017 Name of the Analyst/Institutional Investor : SBI Mutual Fund and its Fund Managers Meeting type : One on one Meeting Location: Mumbai...
07-12-2017
Bigul

US FDA approves Pfizer's Sutent to treat adult patients at high risk of recurrent RCC

 Pfizer has announced that the US Food and Drug Administration has approved a new indication expanding the use of Sutent (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent
18-11-2017
Bigul

Pfizer appoints Albert Bourla as chief operating officer

 Pfizer has announced that Albert Bourla has been named chief operating officer effective January 1, 2018
15-11-2017

Golden Cross Screener: Pfizer gains today despite overall fall in markets

 Pfizer is one of the stocks to break into the Golden Cross Screener today (where the 50 day average share price crossed above the stock's 200 day average). The company had reported its Q2 results a few days ago, announcing a 12% dip in standalone net profit YoY to Rs111.15 crore for the quarter ending 30 September 2017. The stock is currently abuzz on news that the company may have the first patented vaccine - for pneumonia - the Indian government will buy. Pfizer has exclusivity to sell the vaccine until 2026. To see the full screener click here.
13-11-2017

Pfizer Q2 net dips 12% at Rs111.15 crore

 Pfizer's standalone revenue from operations rose to Rs571.11 crore as against Rs557.66 crore for the same period year ago
10-11-2017
Bigul

Press Release / Media Release

 Please find enclosed press release for the financial results for the quarter and half year ended September 30, 2017. Please take the above on record.
10-11-2017
Bigul

Unaudited Financial Results For The Quarter Ended September 30, 2017.

 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and half year ended September 30, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 11:30 a.m. and concluded at 1:45 p.m....
10-11-2017
Bigul

No dearth of suitors for consumer health business, says Pfizer

 Pfizer said the supply challenges would have a negative impact of "several hundred million dollars" this year, moderating in 2018
01-11-2017
Next Page
Close

Let's Open Free Demat Account